{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:50:37Z","timestamp":1791654637587,"version":"4.3.4"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P30GM149331"],"award-info":[{"award-number":["P30GM149331"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32DA007242"],"award-info":[{"award-number":["T32DA007242"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009827","name":"Laura and John Arnold Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA04279"],"award-info":[{"award-number":["R01DA04279"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.josat.2026.210105","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:20:35Z","timestamp":1789428035000},"page":"210105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-effectiveness of technology-assisted buprenorphine for opioid use disorder: Analysis of three randomized trials"],"prefix":"10.1016","volume":"191","author":[{"given":"Kelly R.","family":"Peck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney R.","family":"Batchelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2187-0593","authenticated-orcid":false,"given":"Donald S.","family":"Shepard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey C.","family":"Sigmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.josat.2026.210105_bb0005","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1111\/add.15883","article-title":"Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs","volume":"117","author":"Adams","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2026.210105_bb0010","series-title":"Provisional drug overdose death counts","author":"Ahmad","year":"2025"},{"issue":"2","key":"10.1016\/j.josat.2026.210105_bb0015","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jval.2020.08.2098","article-title":"Disparities in access to opioid treatment programs and office-based buprenorphine treatment across the rural-urban and area deprivation continua: A US nationwide small area analysis","volume":"24","author":"Amiri","year":"2021","journal-title":"Value in Health"},{"issue":"1","key":"10.1016\/j.josat.2026.210105_bb0020","first-page":"1","article-title":"United States life tables, 2020","volume":"71","author":"Arias","year":"2022","journal-title":"National Vital Statistics Reports"},{"issue":"Suppl. 8","key":"10.1016\/j.josat.2026.210105_bb0025","first-page":"S235","article-title":"Cost and utilization outcomes of opioid-dependence treatments","volume":"17","author":"Baser","year":"2011","journal-title":"The American Journal of Managed Care"},{"issue":"4","key":"10.1016\/j.josat.2026.210105_bb0030","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkac048","article-title":"Cost-effectiveness of a telephone-based smoking cessation randomized trial in the lung cancer screening setting","volume":"6","author":"Cao","year":"2022","journal-title":"JNCI Cancer Spectrum"},{"key":"10.1016\/j.josat.2026.210105_bb0035","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.josat.2026.210105_bb0040","author":"Centers for Medicare & Medicaid Services"},{"key":"10.1016\/j.josat.2026.210105_bb0045","author":"Centers for Medicare and Medicaid Services, CMS"},{"key":"10.1016\/j.josat.2026.210105_bb0050","author":"Centers for Medicare and Medicaid Services, CMS"},{"issue":"4","key":"10.1016\/j.josat.2026.210105_bb0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.7036","article-title":"Estimated costs and outcomes associated with use and nonuse of medications for opioid use disorder during incarceration and at release in Massachusetts","volume":"6","author":"Chatterjee","year":"2023","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2026.210105_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.josat.2023.209237","article-title":"Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective","volume":"160","author":"Choi","year":"2024","journal-title":"Journal of Substance Use and Addiction Treatment"},{"issue":"16","key":"10.1016\/j.josat.2026.210105_bb0065","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1056\/NEJMc2312906","article-title":"Buprenorphine dispensing after elimination of the waiver requirement","volume":"390","author":"Chua","year":"2024","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.josat.2026.210105_bb0070","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.1080","article-title":"Cost-effectiveness of increasing buprenorphine treatment initiation, duration, and capacity among individuals who use opioids","volume":"4","author":"Claypool","year":"2023","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.josat.2026.210105_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109478","article-title":"Modeling of overdose and naloxone distribution in the setting of fentanyl compared to heroin","volume":"236","author":"Coffin","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"issue":"25","key":"10.1016\/j.josat.2026.210105_bb0080","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.jacc.2008.09.018","article-title":"Interpreting the results of cost-effectiveness studies","volume":"52","author":"Cohen","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"issue":"7","key":"10.1016\/j.josat.2026.210105_bb0085","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamapsychiatry.2021.0247","article-title":"Cost-effectiveness of treatments for opioid use disorder","volume":"78","author":"Fairley","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.josat.2026.210105_bb0090","author":"Federal Reserve Bank of St. Louis"},{"issue":"9","key":"10.1016\/j.josat.2026.210105_bb0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.29583","article-title":"Economic evaluation of extended-release buprenorphine for persons with opioid use disorder","volume":"6","author":"Flam-Ross","year":"2023","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2026.210105_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108350","article-title":"The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017","volume":"218","author":"Florence","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"9","key":"10.1016\/j.josat.2026.210105_bb0105","doi-asserted-by":"crossref","first-page":"917","DOI":"10.18553\/jmcp.2024.24025","article-title":"Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: A microsimulation model and cost-effectiveness analysis from a US perspective with relevance to Medicaid","volume":"30","author":"Frank","year":"2024","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"key":"10.1016\/j.josat.2026.210105_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109380","article-title":"Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis","volume":"233","author":"Friedman","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.josat.2026.210105_bb0115","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.josat.2026.210105_bb0120","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force","volume":"25","author":"Husereau","year":"2022","journal-title":"Value in Health"},{"issue":"8","key":"10.1016\/j.josat.2026.210105_bb0125","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.27488","article-title":"Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021","volume":"6","author":"Jones C.","year":"2021","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.josat.2026.210105_bb0130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M17-0611","article-title":"Cost-effectiveness of publicly funded treatment of opioid use disorder in California","volume":"168","author":"Krebs","year":"2018","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1016\/j.josat.2026.210105_bb2000","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/add.13729","article-title":"The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California","volume":"112","author":"Krebs","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2026.210105_bb0135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.drugpo.2016.08.004","article-title":"Risk of fentanyl overdose among clients of the Sydney Medically Supervised Injecting Centre","volume":"37","author":"Latimer","year":"2016","journal-title":"The International Journal on Drug Policy"},{"issue":"Suppl. 3","key":"10.1016\/j.josat.2026.210105_bb0140","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s11606-020-06257-4","article-title":"Barriers and facilitators to the use of medications for opioid use disorder: A rapid review","volume":"35","author":"Mackey","year":"2020","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.josat.2026.210105_bb0145","author":"Massachusetts Department of Public Health"},{"issue":"2","key":"10.1016\/j.josat.2026.210105_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2014","author":"Mattick","year":"2014","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.josat.2026.210105_bb0155","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/07418820400095941","article-title":"Long-term cost effectiveness of addiction treatment for criminal offenders","volume":"21","author":"McCollister","year":"2004","journal-title":"Justice Quarterly"},{"key":"10.1016\/j.josat.2026.210105_bb0160","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugalcdep.2019.02.031","article-title":"Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort","volume":"200","author":"Morgan","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2026.210105_bb0165","series-title":"Cost Effectiveness in Health and Medicine","year":"2017"},{"issue":"7","key":"10.1016\/j.josat.2026.210105_bb0170","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jval.2020.12.023","article-title":"Economic evaluations of pharmacologic treatment for opioid use disorder: A systematic literature review","volume":"24","author":"Onuoha","year":"2021","journal-title":"Value in Health"},{"key":"10.1016\/j.josat.2026.210105_bb0175","series-title":"Letter to DEA qualifying practitioners and DEA qualifying other practitioners","author":"Prevoznik","year":"2020"},{"key":"10.1016\/j.josat.2026.210105_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109762","article-title":"Cost-effectiveness of office-based buprenorphine treatment for opioid use disorder","volume":"243","author":"Qian","year":"2023","journal-title":"Drug and Alcohol Dependence"},{"issue":"10","key":"10.1016\/j.josat.2026.210105_bb0185","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"Pt B","key":"10.1016\/j.josat.2026.210105_bb0190","article-title":"Economic analysis of financial incentives for smoking cessation during pregnancy and postpartum","volume":"165","author":"Shepard","year":"2022","journal-title":"Preventive Medicine"},{"key":"10.1016\/j.josat.2026.210105_bb0195","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/HCR.0000000000000827","article-title":"Cost-effectiveness of cardiac rehabilitation in older adults with coronary heart disease","volume":"44","author":"Shepard","year":"2024","journal-title":"Journal of Cardiopulmonary Rehabilitation and Prevention"},{"issue":"25","key":"10.1016\/j.josat.2026.210105_bb0200","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMc1610047","article-title":"Interim buprenorphine vs. waiting list for opioid dependence","volume":"375","author":"Sigmon","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.josat.2026.210105_bb0205","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.31910","article-title":"Technology-assisted buprenorphine treatment in nonrural and rural settings: Two randomized clinical trials","volume":"6","author":"Sigmon","year":"2023","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2026.210105_bb0210","author":"Social Security Administration"},{"key":"10.1016\/j.josat.2026.210105_bb0215","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.josat.2026.210105_bb0220","author":"Substance Abuse and Mental Health Services Administration, SAMHSA"},{"key":"10.1016\/j.josat.2026.210105_bb0225","author":"Substance Abuse and Mental Health Services Administration, SAMHSA"},{"key":"10.1016\/j.josat.2026.210105_bb0230","author":"Substance Abuse and Mental Health Services Administration, SAMHSA"},{"key":"10.1016\/j.josat.2026.210105_bb0235","author":"US Bureau of Labor Statistics"},{"key":"10.1016\/j.josat.2026.210105_bb0240","author":"US Bureau of Labor Statistics"},{"key":"10.1016\/j.josat.2026.210105_bb0245","author":"US Department of Justice"},{"issue":"1","key":"10.1016\/j.josat.2026.210105_bb0250","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: Development, challenges and opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Molecular Psychiatry"},{"issue":"15","key":"10.1016\/j.josat.2026.210105_bb0255","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029215","article-title":"Health and economic impacts of implementing produce prescription programs for diabetes in the United States: A microsimulation study","volume":"12","author":"Wang","year":"2023","journal-title":"Journal of the American Heart Association"},{"issue":"4","key":"10.1016\/j.josat.2026.210105_bb0260","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/add.13219","article-title":"Measuring benefits of opioid misuse treatment for economic evaluation: Health-related quality of life of opioid-dependent individuals and their spouses as assessed by a sample of the US population","volume":"111","author":"Wittenberg","year":"2016","journal-title":"Addiction"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875926002250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875926002250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:32:41Z","timestamp":1791653561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875926002250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":53,"alternative-id":["S2949875926002250"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2026.210105","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of technology-assisted buprenorphine for opioid use disorder: Analysis of three randomized trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2026.210105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"210105"}}